Clinical Trials · NCT07002177
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Forward Pharmaceuticals Co., Ltd.
- Enrollment
- 196
- Start date
- Jun 2025
- Locations
- 1 site, China
- Primary endpoint
- Phase Ib- Dose-Limiting Toxicity (DLT).